FDA Doctor-Like Assessment Framework for AI-Enabled Medical Devices
OVERVIEWThe FDA is actively considering a "doctor-like assessment" model for evaluating AI-enabled medical devices, according to reporting by Axios. This framework would assess AI systems by the standard of a competent clinician rather than purely by technical performance metrics—a significant conceptual shift in how the agency evaluates AI software as a medical device. Separately, Becker's Hospital Review reports the FDA has outlined a proposed framework centered on a "predetermined change control plan" (PCCP), which would allow AI device manufacturers to submit an upfront plan describing how an algorithm is expected to learn and adapt post-market. This addresses a longstanding gap: traditional device regulation assumed static software, while modern AI systems continuously update. The PCCP mechanism would permit adaptive AI without requiring a new 510(k) or PMA submission for each algorithmic change, provided changes fall within the pre-approved envelope. The Clinical Trial Vanguard reports that the FDA has already authorized approximately 1,500 AI medical devices, but that the evidence base for most of them is still catching up to their market presence. This post-market evidence gap is a central concern for patient safety advocates and researchers. A Frontiers study further documents a "fairness paradox" in FDA regulatory summaries—public-facing documentation often lacks transparency about subgroup performance and equity considerations. Together, these developments suggest the FDA…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.